GB1098151A - Membrane penetrant compositions comprising dialkyl sulfoxides - Google Patents

Membrane penetrant compositions comprising dialkyl sulfoxides

Info

Publication number
GB1098151A
GB1098151A GB4320964A GB4320964A GB1098151A GB 1098151 A GB1098151 A GB 1098151A GB 4320964 A GB4320964 A GB 4320964A GB 4320964 A GB4320964 A GB 4320964A GB 1098151 A GB1098151 A GB 1098151A
Authority
GB
United Kingdom
Prior art keywords
agent
histamine
specified
sodium
anaesthetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB4320964A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
James River Corp of Nevada
Original Assignee
Crown Zellerbach Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crown Zellerbach Corp filed Critical Crown Zellerbach Corp
Publication of GB1098151A publication Critical patent/GB1098151A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Abstract

Pharmaceutical preparations comprise a dialkyl sulphoxide in which each alkyl group contains up to 4 carbon atoms and an effective amount of an antibacterial substance, insulin, a vitamin, a steroid, a cytotoxic agent, an antigen, a neuropharmacological agent, a radiopaque agent, a diagnostic dye, histamine, heparin, a general anaesthetic, a local anaesthetic, an analgesic, or an anti-histamine. The preferred dialkyl sulphoxide is dimethyl sulphoxide. The preparations may contain a pharmaceutically acceptable carrier and may be in the form of a solution, cream, ointment, or suppository. Conventional excipients, e.g. surfactants, buffers or gelling agents, may also be included. The antibacterial substance may be iodine, penicillin or sodium sulfadiazine. A specified steroid is dexamethasone 21-phosphate. Specified cytotoxic agents are methotrexate and thio-TEPA. The antigen may be an allergenic extract of tree pollen. The neuropharmacological agent may be aminophylline. The diagnostic dye may be Evans Blue dye. The general anaesthetic may be sodium pentobarbital. The local anaesthetic may be procaine, or lidocaine. A specified analgesic is sodium salicylate. The anti-histamine may be diphenhydramine hydrochloride. The exemplified vitamin is nicotinic acid. The exemplified radiopaque agent is iodine in aqueous sodium iodide solution.
GB4320964A 1963-12-09 1964-12-08 Membrane penetrant compositions comprising dialkyl sulfoxides Expired GB1098151A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32890863A 1963-12-09 1963-12-09
US32915163A 1963-12-09 1963-12-09

Publications (1)

Publication Number Publication Date
GB1098151A true GB1098151A (en) 1968-01-10

Family

ID=26986565

Family Applications (2)

Application Number Title Priority Date Filing Date
GB3997867A Expired GB1106170A (en) 1963-12-09 1964-12-08 Introduction of physiologically active substances into animal tissues
GB4320964A Expired GB1098151A (en) 1963-12-09 1964-12-08 Membrane penetrant compositions comprising dialkyl sulfoxides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB3997867A Expired GB1106170A (en) 1963-12-09 1964-12-08 Introduction of physiologically active substances into animal tissues

Country Status (5)

Country Link
BR (1) BR6465159D0 (en)
ES (1) ES306377A1 (en)
GB (2) GB1106170A (en)
IL (1) IL22493A (en)
NL (1) NL140731B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2282263A1 (en) * 1974-08-23 1976-03-19 Fisons Ltd NEW SEDATIVE COMPOSITIONS
GB2119248A (en) * 1982-04-28 1983-11-16 John Kenneth Mcmullen Insulin formulations and method of producing them
EP0189861A2 (en) * 1985-01-26 1986-08-06 Showa Denko Kabushiki Kaisha Percutaneous absorption accelerator for ionic water-soluble medicine
WO1998000158A1 (en) * 1996-07-03 1998-01-08 Alza Corporation Non-aqueous polar aprotic peptide formulations
AU775395B2 (en) * 1996-07-03 2004-07-29 Alza Corporation Non-aqueous polar aprotic peptide formulations

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2282263A1 (en) * 1974-08-23 1976-03-19 Fisons Ltd NEW SEDATIVE COMPOSITIONS
GB2119248A (en) * 1982-04-28 1983-11-16 John Kenneth Mcmullen Insulin formulations and method of producing them
EP0189861A2 (en) * 1985-01-26 1986-08-06 Showa Denko Kabushiki Kaisha Percutaneous absorption accelerator for ionic water-soluble medicine
EP0189861A3 (en) * 1985-01-26 1988-02-17 Showa Denko Kabushiki Kaisha Percutaneous absorption accelerator for ionic water-soluble medicine
WO1998000158A1 (en) * 1996-07-03 1998-01-08 Alza Corporation Non-aqueous polar aprotic peptide formulations
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US6124261A (en) * 1996-07-03 2000-09-26 Alza Corporation Non-aqueous polar aprotic peptide formulations
US6235712B1 (en) 1996-07-03 2001-05-22 Alza Corporation Non-aqueous polar aprotic peptide formulations
AU739169B2 (en) * 1996-07-03 2001-10-04 Alza Corporation Non-aqueous polar aprotic peptide formulations
AU775395B2 (en) * 1996-07-03 2004-07-29 Alza Corporation Non-aqueous polar aprotic peptide formulations
CZ299464B6 (en) * 1996-07-03 2008-08-06 Alza Corporation Implantable drug delivery system, process for its preparation and use of peptide compound formulation
CZ300378B6 (en) * 1996-07-03 2009-05-06 Alza Corporation Stable non-aqueous formulation of a peptide compound and method for preparation thereof

Also Published As

Publication number Publication date
GB1106170A (en) 1968-03-13
IL22493A (en) 1968-10-24
BR6465159D0 (en) 1973-08-02
ES306377A1 (en) 1965-05-01
NL6414293A (en) 1965-06-10
NL140731B (en) 1974-01-15

Similar Documents

Publication Publication Date Title
KR920021139A (en) Pharmaceutical composition
NL194165B (en) Carbostyril derivatives, methods of preparation thereof and pharmaceutical compositions containing these derivatives. Derivatives of quinolonyl-2-aminocarboxylic acids and pharmaceutical preparations containing these derivatives.
BR0211613A (en) Pharmaceutical compositions containing beta-lapachone or derivatives or analogs thereof, and processes for their use
US3070499A (en) Parenteral aqueous solutions of fat soluble vitamins
IT1062053B (en) PHARMACEUTICALLY ACTIVE AMMINOGUANIDINE PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT COMMENGOMO
GB1098151A (en) Membrane penetrant compositions comprising dialkyl sulfoxides
GB1317184A (en) Steroid-containing pharmaceutical preparations
GB1115893A (en) Pharmaceutical anti-allergic compositions
US1928346A (en) Anaesthetic
EG10508A (en) Method for preparation of 5-aryl 2,3-dihydro-2,2(or 3,3)dimethyl-5h-imidazo(2,1-a)isoindol-5-ols and 2(4,4(5,5)dimethyl-2-imidazolin-2-yl)bensophenone acid addition salts used as autidepressant drug
US3526698A (en) Stabilization of levo-3-(3,4-dihydroxyphenyl)-2-methylalanine with sodium bisulfite and sorbitol
GB1270049A (en) New pharmaceutical product
ES2128353T3 (en) TOPIC COMPOSITION CONTAINING PENCICLOVIR.
GB1081551A (en) Injectable oil compositions
GB1133800A (en) Pharmaceutical compositions
KR900016156A (en) Quinoxaline derivatives and ulcers
GB1359044A (en) Quinoline derivatives
EP2803354A1 (en) Combination of polyacrylic acid and 2-amino-2-methylpropanol for use in the treatment of Herpes infections
DE2013039A1 (en) Medicinal tablet for oral administration
DE3065087D1 (en) Piperidine derivatives of 3-hydroxy-thiophene-2-carboxylic acid esters, their preparation, and pharmaceutical preparations containing them
Swyer Progestogens and their clinical uses: Part I
EP0056681A2 (en) Levonantradol and N-methyllevonantradol formulations
Kamel et al. The value of premedication in diminishing salivary secretions
GB1077039A (en) A choline derivative and therapeutic compositions containing it
ES342394A1 (en) Novel Benzylaminoimidazoline Derivatives, the preparation thereof and Compositions containing the same